Discovery of dengue virus NS4B inhibitors

Qing Yin Wang, Hongping Dong, Bin Zou, Ratna Karuna, Kah Fei Wan, Jing Zou, Agatha Susila, Andy Yip, Chao Shan, Kim Long Yeo, Haoying Xu, Mei Ding, Wai Ling Chan, Feng Gu, Peck Gee Seah, Wei Liu, Suresh B. Lakshminarayana, Cong Bao Kang, Julien Lescar, Francesca Blasco & 2 others Paul W. Smith, Pei-Yong Shi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50, > 20 μM). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial "hit" (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients.

Original languageEnglish (US)
Pages (from-to)8233-8244
Number of pages12
JournalJournal of Virology
Volume89
Issue number16
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Dengue virus
Dengue Virus
Amino Acids
Viral Structures
Replicon
Pharmaceutical Chemistry
Viremia
Virus Diseases
Therapeutics
Culicidae
Libraries
Antiviral Agents
Vaccines
Pharmacokinetics
Mutation
replicon
amino acids
transmembrane proteins
Infection
viremia

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Wang, Q. Y., Dong, H., Zou, B., Karuna, R., Wan, K. F., Zou, J., ... Shi, P-Y. (2015). Discovery of dengue virus NS4B inhibitors. Journal of Virology, 89(16), 8233-8244. https://doi.org/10.1128/JVI.00855-15

Discovery of dengue virus NS4B inhibitors. / Wang, Qing Yin; Dong, Hongping; Zou, Bin; Karuna, Ratna; Wan, Kah Fei; Zou, Jing; Susila, Agatha; Yip, Andy; Shan, Chao; Yeo, Kim Long; Xu, Haoying; Ding, Mei; Chan, Wai Ling; Gu, Feng; Seah, Peck Gee; Liu, Wei; Lakshminarayana, Suresh B.; Kang, Cong Bao; Lescar, Julien; Blasco, Francesca; Smith, Paul W.; Shi, Pei-Yong.

In: Journal of Virology, Vol. 89, No. 16, 2015, p. 8233-8244.

Research output: Contribution to journalArticle

Wang, QY, Dong, H, Zou, B, Karuna, R, Wan, KF, Zou, J, Susila, A, Yip, A, Shan, C, Yeo, KL, Xu, H, Ding, M, Chan, WL, Gu, F, Seah, PG, Liu, W, Lakshminarayana, SB, Kang, CB, Lescar, J, Blasco, F, Smith, PW & Shi, P-Y 2015, 'Discovery of dengue virus NS4B inhibitors', Journal of Virology, vol. 89, no. 16, pp. 8233-8244. https://doi.org/10.1128/JVI.00855-15
Wang QY, Dong H, Zou B, Karuna R, Wan KF, Zou J et al. Discovery of dengue virus NS4B inhibitors. Journal of Virology. 2015;89(16):8233-8244. https://doi.org/10.1128/JVI.00855-15
Wang, Qing Yin ; Dong, Hongping ; Zou, Bin ; Karuna, Ratna ; Wan, Kah Fei ; Zou, Jing ; Susila, Agatha ; Yip, Andy ; Shan, Chao ; Yeo, Kim Long ; Xu, Haoying ; Ding, Mei ; Chan, Wai Ling ; Gu, Feng ; Seah, Peck Gee ; Liu, Wei ; Lakshminarayana, Suresh B. ; Kang, Cong Bao ; Lescar, Julien ; Blasco, Francesca ; Smith, Paul W. ; Shi, Pei-Yong. / Discovery of dengue virus NS4B inhibitors. In: Journal of Virology. 2015 ; Vol. 89, No. 16. pp. 8233-8244.
@article{11cad08a3de84198b494e9ed40cab35d,
title = "Discovery of dengue virus NS4B inhibitors",
abstract = "The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50{\%} effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50, > 20 μM). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial {"}hit{"} (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients.",
author = "Wang, {Qing Yin} and Hongping Dong and Bin Zou and Ratna Karuna and Wan, {Kah Fei} and Jing Zou and Agatha Susila and Andy Yip and Chao Shan and Yeo, {Kim Long} and Haoying Xu and Mei Ding and Chan, {Wai Ling} and Feng Gu and Seah, {Peck Gee} and Wei Liu and Lakshminarayana, {Suresh B.} and Kang, {Cong Bao} and Julien Lescar and Francesca Blasco and Smith, {Paul W.} and Pei-Yong Shi",
year = "2015",
doi = "10.1128/JVI.00855-15",
language = "English (US)",
volume = "89",
pages = "8233--8244",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "16",

}

TY - JOUR

T1 - Discovery of dengue virus NS4B inhibitors

AU - Wang, Qing Yin

AU - Dong, Hongping

AU - Zou, Bin

AU - Karuna, Ratna

AU - Wan, Kah Fei

AU - Zou, Jing

AU - Susila, Agatha

AU - Yip, Andy

AU - Shan, Chao

AU - Yeo, Kim Long

AU - Xu, Haoying

AU - Ding, Mei

AU - Chan, Wai Ling

AU - Gu, Feng

AU - Seah, Peck Gee

AU - Liu, Wei

AU - Lakshminarayana, Suresh B.

AU - Kang, Cong Bao

AU - Lescar, Julien

AU - Blasco, Francesca

AU - Smith, Paul W.

AU - Shi, Pei-Yong

PY - 2015

Y1 - 2015

N2 - The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50, > 20 μM). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial "hit" (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients.

AB - The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50, > 20 μM). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial "hit" (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=84938152526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938152526&partnerID=8YFLogxK

U2 - 10.1128/JVI.00855-15

DO - 10.1128/JVI.00855-15

M3 - Article

VL - 89

SP - 8233

EP - 8244

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 16

ER -